Health care stocks were lower Monday afternoon, with the NYSE Health Care Index easing 0.1% and the Health Care Select Sector SPDR Fund (XLV) down 0.3%.
The iShares Biotechnology ETF (IBB) shed 0.2%.
In corporate news, AbbVie (ABBV) shares tumbled 12%. The company said its two phase 2 trials assessing emraclidine in adult patients with schizophrenia and acute exacerbation of psychotic symptoms failed to meet their primary goal.
Cigna (CI) shares climbed past 7%. The health insurer said it's not pursuing a combination with Humana (HUM) and is on track to meet its full-year earnings target. Humana shares fell almost 2%.
Novavax (NVAX) said Monday that the US Food and Drug Administration has lifted a clinical hold on an investigational new-drug application for its Covid-Influenza combination and stand-alone flu vaccine candidates. Its shares popped 2%.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。